email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

ISSN: 2637-4706

Drug Designing & Intellectual Properties International Journal

Research Article(ISSN: 2637-4706)

The Consciousness Energy Healing Treatment and Its Impact on the Isotopic Abundance Ratio Analysis of Flutamide Volume 3 - Issue 5

Mahendra Kumar Trivedi1, Alice Branton1, Dahryn Trivedi1 and Snehasis Jana2*

  • 1Trivedi Global, Inc., Henderson, USA
  • 2Trivedi Science Research Laboratory Pvt. Ltd., Thane, India.

Received: January 30, 2021;   Published: February 25, 2021

Corresponding author: Snehasis Jana, Trivedi Science Research Laboratory Pvt. Ltd. Thane (W), Maharashtra, India

DOI: 10.32474/DDIPIJ.2021.03.000175

Abstract PDF

Abstract

Flutamide is used to treat prostate cancer, which acts by blocking the action of exogenous testosterone binding through its androgen receptor. This study was designed and performed to investigate the impact of the Trivedi Effect®-Consciousness Energy Healing Treatment on the structural properties and the isotopic abundance ratio of flutamide using LC-MS and GC-MS spectroscopy. Flutamide sample was divided into control and treated parts. Only the treated flutamide received the Trivedi Effect®-Consciousness Energy Healing Treatment remotely by a famous Biofield Energy Healer, Mahendra Kumar Trivedi. The LC-MS spectra of both the samples at Retention time (Rt) ~3.4 minutes exhibited the mass of the deprotonated molecular ion peak at m/z 275 [M-H]-. The peak area of the Biofield Energy Treated flutamide was significantly increased by 34.29% compared to the control sample, which indicated that the solubility profile of the Biofield Energy Treated flutamide was significantly increased compared to the control sample. The LC-MS based isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the Biofield Energy Treated flutamide was significantly decreased by 15.85% compared with the control sample. The GC-MS based isotopic abundance ratio of PM+1/PM in the Biofield Energy Treated flutamide was also decreased by 49.62% compared with the control sample. The results indicated that the 13C, 2H, 15N, and 17O contributions from (C11H11F3N2O3+ to m/z 277 in the Biofield Energy Treated flutamide were significantly increased compared with the control sample. The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the Biofield Energy Treated flutamide was significantly decreased compared to the control sample. The changes in the peak area and isotopic abundance could be due to changes in nuclei possibly through the interference of neutrino via the Trivedi Effect®-Consciousness Energy Healing Treatment. The new form of treated flutamide was formed that might have decrease the chemical bond strength and stability, but may increase solubility, bioavailability, and efficacy, which could be very much useful to design more efficacious pharmaceutical formulations against prostate cancer, androgen-dependent skin and hair conditions including acne, seborrhea, hirsutism, and scalp hair loss, hyperandrogenism, as well useful for feminizing hormone therapy aimed at transgender women.

Keywords: Flutamide; The Trivedi Effect®; Biofield Energy; Consciousness Energy; LC-MS; GC-MS

Introduction

Flutamide is a Nonsteroidal Antiandrogen (NSAA) which blocks the action of both endogenous and exogenous testosterone by inhibiting the androgen receptor. Further, it is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis and it is capable of inhibiting prostatic nuclear uptake of androgen [1-3]. Flutamide can be used independently for the treatment or in combination with other medications and radiation treatments [4]. It is used primarily to treat men with prostate cancer [5]. The testosterone hormone aids prostate cancer to grow and spread [6]. It is also used in the treatment of androgen-dependent problems, i.e., acne, seborrhea, hirsutism, scalp hair loss, and hyperandrogenism. It can be used as a constituent of feminizing hormone therapy for transgender women [7]. Overdose of flutamide may cause anorexia, ataxia, piloerection, hypoactivity, slow respiration, and/or lacrimation, emesis, tranquilization, and methemoglobinemia [8].The physicochemical properties of a pharmaceutical compound in the formulation is very much important and decide the rate of dissolution, absorption, bioavailability, and efficacy in the body [9]. It was observed that the Trivedi Effect®-Consciousness Energy Healing Treatment (Biofield Energy Healing Treatment) has the significant impact on solubility and bioavailability by directly altering the isotope composition, physicochemical and thermal behaviors of various nutraceutical and pharmaceutical compounds [10-12]. The Trivedi Effect® is a natural and only technically established phenomenon in which an individual can harness this inherently intelligent energy from the “Universal Energy Field” and transfer it anywhere on the planet via the possible mediation of neutrinos [13]. “Biofield” is the electromagnetic energy field which exists surrounding the living organisms, generated by the continuous movement of the electrically charged particles (ions, cells, etc.) inside the body. It can transmit the electromagnetic energy in the form of bio-photons and this process is called Biofield Energy Healing Treatment [14,15]. Biofield Therapies (Energy Medicine) have been reported with significant outcomes against various disease conditions [16]. The National Center for Complementary and Alternative Medicine (NCCAM) has recognized and accepted Biofield Energy Healing as a Complementary and Alternative Medicine (CAM) health care approach along with other therapies, medicines, and practices such as yoga, Qi Gong, Tai Chi, hypnotherapy, Reiki, etc. [17]. These CAM therapies have been accepted by most of the U.S.A. population with several advantages [18]. The significant outcome of the Trivedi Effect®-Consciousness Energy Healing Treatment has been widely reported. It has been reported altering the characteristic properties of the several non-living materials and living object(s), i.e.organic compounds [19, 20]. metals and ceramic [21-22]. polymer [23]. crops [24]. nutraceuticals [25, 26], microbes [27, 28].etc. The stable isotope ratio and its analysis have various applications in different field of science for understanding the isotope effects resulting from the variation of the isotopic composition of the molecule [29, 30]. Isotope ratio analysis can be performed by using the conventional Mass Spectrometry (MS) techniques such as Gas Chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS) in low micromolar concentration with sufficient precision [30, 31]. The Trivedi Effect®-Consciousness Energy Healing Treatment could be an economical approach for designing better pharmaceuticals formulations. Therefore, in this study, special attention was taken to improve the physicochemical parameters of the pharmaceutical product, e.g., flutamide. Hence, LC-MS and GC-MS were used in this study to characterize the structural properties and evaluate the isotopic abundance ratio analysis of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the Trivedi Effect®-Consciousness Energy Healing Treated flutamide compared to the control sample.

Materials and Methods

Chemicals and Reagents

The test compound flutamide was purchased from Tokyo Chemical Industry Co., Ltd., Japan. Whereas, the other chemicals and reagents used during the experiments were of analytical grade purchased in India.

Consciousness Energy Healing Treatment Strategies

The test sample flutamide was divided into two parts. One part of the sample did not receive the Biofield Energy Treatment known as control sample. Further, the control sample was treated with a “sham” healer, who did not have any knowledge about the Biofield Energy. However, the other part of flutamide was received the Trivedi Effect®-Consciousness Energy Healing Treatment remotely under standard laboratory conditions for 3 minutes by the wellknown Biofield Energy Healer, Mahendra Kumar Trivedi, USA, and known as the Biofield Energy Treated flutamide. After completion of the treatment, both the samples were kept in sealed conditions and characterized using sophisticated analytical techniques.

Characterization

Liquid Chromatography-Mass Spectrometry (LC-MS) Analysis and Calculation of Isotopic Abundance Ratio

The LC-MS analysis of flutamide was carried out with the help of LC-MS Thermo Fisher Scientific, the USA equipped with an ion trap detector connected with a triple-stage quadrupole mass spectrometer. The column used here was a reversed phase Thermo Scientific Synchronis C18 (Length-250 mm X ID 4.6 mm X 5 micron), maintained at 25°C. Methanol was the diluent for the sample preparation. 10 µL of flutamide solution was injected, and the analyte was eluted using 92% acetonitrile + 8% 10 mM ammonium acetate pumped at a constant flow rate of 1 mL/min (total run time was 10 min). Peaks were monitored at 300 nm using the PDA detector and were performed under -ve ESI mode. The natural abundance of each isotope (C, O, H, N, and F) can be predicted from the comparison of the height of the isotope peak with respect to the base peak. The values of the natural isotopic abundance of the common elements are obtained from the literature [30,32-34]. The LC-MS based isotopic abundance ratio (PM+1/PM) of the Biofield Energy Treated flutamide was calculated compared with the control sample using equation 1.

% Change in isotopic abundance ratio = [(IARTreated IARControl)/ IARControl] x 100;Equation (1).

Where IARTreated = isotopic abundance ratio in the treated flutamide and IARControl = isotopic abundance ratio in the control flutamide.

Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

GC-MS of the flutamide was analyzed with the help of Perkin Elmer Gas chromatograph equipped with a PE-5MS (30M x 250 micros x 0.250 microns) capillary column and coupled to a single quadrupole mass detector was operated with electron impact (EI) ionization (+ve ion mode). The oven temperature was programmed from 80°C (14 min hold) to 250°C (3 min hold) @ 10°C /min (total run time 25 min). The sample was prepared taking 60 mg of the flutamide is in 2 ml methanol as a diluent. The GC-MS based isotopic abundance ratio (PM+1/PM) of the Biofield Energy Treated flutamide was calculated compared with the control sample using equation 1.

Results and Discussion

Liquid Chromatography-Mass Spectrometry (LC-MS)

Figure 1: Liquid chromatograms of the control and Biofield Energy Treated flutamide.

Lupinepublishers-openaccess-drug-designing-journal

Figure 2: Mass spectra of the control and Biofield Energy Treated flutamide at Rt 3.4 minutes.

Lupinepublishers-openaccess-drug-designing-journal

The chromatograms and mass spectra of both the samples of flutamide are shown in (Figures 1 & 2), respectively. Both the sample showed a single major chromatographic peak at the Retention time (Rt) of 3.41 minutes in the chromatograms (Figure 1). The peak area of the Biofield Energy Treated flutamide was significantly increased by 34.29% compared to the control sample, which indicated that the solubility profile of the Biofield Energy Treated sample was significantly increased compared to the control sample.T he literature reported molecular mass peak [M]+ of flutamide was at m/z 276 in the spectrum [35]. The flutamide showed the deprotonated molecular ion peak at m/z 275.17 [M-H]- (calculated for C11H10F3N2O3-, 175.06) along with other fragmentation peaks (Figure 2).

The LC-MS spectra of both the samples showed the mass of the molecular ion peak at m/z 275.08 [M-H]- with relative intensity of 100%. The theoretical calculation of PM+1 for flutamide was presented as below:

P (13C) = [(11 x 1.1%) x 100% (the actual size of the M- peak)] / 100% = 12.1%

P (2H) = [(10 x 0.015%) x 100%] / 100%= 0.15%

P (15N) = [(2 x 0.4%) x 100%] / 100% = 0.8%

P (17O) = [(3 x 0.04%) x 100%] / 100% = 0.12%

PM+1, i.e. 13C, 2H, 15N, and 17O contributions from (C11H10F3N2O3)- to m/z 276.08 = 13.17%

From the above calculation, it has been found that 13C and 15N have major contributions from (C11H10F3N2O3)- to m/z 276.08. The theoretical calculation (13.17%) was closely matched to the control sample (12.68%).

The LC-MS based isotopic abundance ratio analysis PM and PM+1 for flutamide near m/z 275 and 276, respectively of the control and Biofield Energy Treated samples, which were obtained from the observed relative peak intensities of [M-] and [(M+1)-] peaks, respectively (Table 1). The percent change of the isotopic abundance ratio (PM+1/PM) in the treated flutamide was significantly decreased by 15.85% compared with the control sample (Table 1). Therefore, it was concluded that the 13C, 2H, 15N, and 17O contributions from (C11H10F3N2O3)- to m/z 276 in the treated flutamide were significantly decreased compared to the control sample.

Table 1: LC-MS based isotopic abundance analysis results in Biofield Energy Treated flutamide compared to the control sample.

lupinepublishers-openaccess-drug-designing-journal

PM: the relative peak intensity of the parent molecular ion [M+]; PM+1: the relative peak intensity of the isotopic molecular ion [(M+1)+], M: mass of the parent molecule.

Gas Chromatography-Mass Spectrometry (GC-MS) Analysis

The GC-MS chromatograms showed the presence of a single chromatographic peak at the retention time of ~18.8 minutes in both the samples of flutamide (Figures 3&4). The parent molecular ion peak of flutamide at m/z 276 [M]+ (calculated for C11H11F3N2O3+, 276.07) in the control sample and Biofield Energy Treated sample, along with the fragment ion peaks near m/z 246, 233, 206, 187, 71, and 43 (Figures 3&4) which corresponded to the molecular formula C10H9F3N2O22+, C9H8F3N2O2+, C7H5F3N2O22+, C7H5F2N2O2+, C4H7O+, and C3H7+, respectively were proposed (Figure 5).

Figure 3: The GC-MS chromatogram and mass spectra of the control flutamide.

Lupinepublishers-openaccess-drug-designing-journal

Figure 4: The GC-MS chromatogram and mass spectra of the Biofield Energy Treated flutamide.

Lupinepublishers-openaccess-drug-designing-journal

Figure 5: Proposed fragmentation pattern of flutamide.

Lupinepublishers-openaccess-drug-designing-journal

The GC-MS spectra of both the control and Biofield Energy Treated flutamide showed the mass of the molecular ion peak [M]+ at m/z 276 (calculated for C11H11F3N2O3+, 276.07). The theoretical calculation of PM+1 for flutamide was presented as below:

P (13C) = [(11 x 1.1%) x 2.62% (the actual size of the M+ peak)] / 100% = 0.32%

P (2H) = [(11 x 0.015%) x 2.62%] / 100%= 0.004%

P (15N) = [(2 x 0.4%) x 2.62%] / 100% = 0.02%

P (17O) = [(3 x 0.04%) x 2.62%] / 100% = 0.003%

PM+1, i.e. 13C, 2H, 15N, and 17O contributions from (C11H11F3N2O3)+ to m/z 277 = 0.37%

The calculated isotope abundance (0.37%) was close to the experimental value 0.39% (Table 2). From the above calculation, it has been found that 13C and 15N have major contribution to m/z 277.

The GC-MS based isotopic abundance ratio of PM+1/PM in the Biofield Energy Treated flutamide was significantly decreased by 49.62% compared with the control sample (Table 2). Hence, 13C, 2H, 15N, and 17O contributions from (C11H11F3N2O3)+ to m/z 277 in the Biofield Energy Treated sample were increased compared with the control sample. The data confirmed the structure of the sample as flutamide. The peak area and isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the Biofield Energy Treated flutamide were significantly increased compared to the control sample. According to modern physics, the neutrino is an elementary particle which changes identities. It is only possible if the neutrinos possess mass and have the ability to interchange their phase from one phase to another internally. Therefore, the neutrinos have the capability to interact with protons and neutrons in the nucleus, which indicated a close relation between neutrino and the isotope formation [12, 30, 31]. The altered isotopic composition in the molecular level of the treated flutamide might have altered the neutron to proton ratio in the nucleus. It can be assumed that the alterations in the isotopic abundance could be due to the change in nuclei by the interference of neutrino particles via the Trivedi Effect®-Consciousness Energy Healing Treatment.

Table 2: GC-MS based isotopic abundance analysis results of Biofield Energy Treated flutamide compared to the control samples.

lupinepublishers-openaccess-drug-designing-journal

PM: the relative peak intensity of the parent molecular ion [M+]; PM+1: the relative peak intensity of the isotopic molecular ion [(M+1)+]; M: mass of the parent molecule.

The improved isotopic abundance ratios 2H/1H or 13C/12C or 15N/14N or 17O/16O would highly influence the atomic bond vibration of treated flutamide [36]. The decreased isotopic abundance ratio of the Consciousness Energy Healing Treated flutamide would weak the chemical bonds and decrease the stability. The Trivedi Effect®-Consciousness Energy Healing Treated flutamide might improve the solubility, bioavailability, and therapeutic efficacy compared to the control sample. The new form of Biofield Energy Treated flutamide would be very much useful to design better pharmaceutical formulations against prostate cancer, androgen-dependent skin and hair conditions including acne, seborrhea, hirsutism, and scalp hair loss, hyperandrogenism, as well useful for feminizing hormone therapy aimed at transgender women.

Conclusion

The Trivedi Effect®-Consciousness Energy Healing Treatment showed a significant impact on the isotopic abundance ratio and peak area of flutamide. The LC-MS spectra of both the samples at Retention time (Rt) ~3.4 minutes exhibited the mass of the deprotonated molecular ion peak at m/z 275 [M-H]-. The peak area of the Biofield Energy Treated flutamide was significantly increased by 34.29% compared to the control sample, which indicated that the solubility profile of the Biofield Energy Treated flutamide was significantly increased compared to the control sample. The LC-MS based isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the Biofield Energy Treated flutamide was significantly decreased by 15.85% compared with the control sample. The GC-MS based isotopic abundance ratio of PM+1/PM in the Biofield Energy Treated flutamide was also decreased by 49.62% compared with the control sample. The results indicated that the 13C, 2H, 15N, and 17O contributions from (C11H11F3N2O3)+ to m/z 277 in the Biofield Energy Treated flutamide were significantly increased compared with the control sample. The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the Biofield Energy Treated flutamide was significantly decreased compared to the control sample. The changes in the peak area and isotopic abundance could be due to changes in nuclei possibly through the interference of neutrino via the Trivedi Effect®-Consciousness Energy Healing Treatment. The new form of treated flutamide was formed that might have decrease the chemical bond strength and stability, but may increase bioavailability, and efficacy, which could be very much useful to design more efficacious pharmaceutical formulations against prostate cancer, androgen-dependent skin and hair conditions including acne, seborrhea, hirsutism, and scalp hair loss, hyperandrogenism, as well useful for feminizing hormone therapy aimed at transgender women.

Acknowledgement

The authors are grateful to Sophisticated Instrumentation Centre for Applied Research & Testing (SICART) India, Trivedi Science, Trivedi Global, Inc., Trivedi Testimonials, and Trivedi Master Wellness for their assistance and support during this work.

References

  1. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies.
  2. Index Nominum (2000) International Drug Directory. Taylor & Francis: 466.
  3. Budavari S (2003) The Merck index. Whitehouse Station: Merck and Co Inc.
  4. Salgado HRN, Menezes M, Storti MPB (2005) Determination of flutamide in tablets by high-performance liquid chromatography. Acta Farm Bonaer 24(2): 246-249.
  5. Goldspiel BR, Kohler DR (1990) Flutamide: An antiandrogen for advanced prostate cancer. DICP 24(6): 616-623.
  6. Sufrin G, Coffey DS (1976) Flutamide Mechanism of action of a new nonsteroidal antiandrogen. Invest Urol 13(6): 429-434.
  7. https://en.wikipedia.org/wiki/Flutamide.
  8. Mizuno K, Hayashi Y, Kojima Y, Kurokawa S, Sasaki S, et al. (2006) Influence for testicular development and histological peculiarity in the testes of flutamide-induced cryptorchid rat model. International Journal of Urology 14(1): 67-72.
  9. Chereson R (2009) Bioavailability, bioequivalence, and drug selection. In: Makoid CM, Vuchetich PJ, Banakar UV (Eds) Basic pharmacokinetics (1st Edn), Pharmaceutical Press, London.
  10. Branton A, Jana S (2017) Effect of the biofield energy healing treatment on the pharmacokinetics of 25-hydroxyvitamin D3 [25(OH)D3] in rats after a single oral dose of vitamin D3. American Journal of Pharmacology and Phytotherapy 2(1): 11-18.
  11. Trivedi MK, Branton A, Trivedi D, Nayak G, Wellborn BD, et al. (2017) Effect of the energy of consciousness (the Trivedi Effect®) on the structural properties and isotopic abundance ratio of magnesium gluconate using LC-MS and NMR spectroscopy. Advances in Biochemistry 5(1): 7-15.
  12. Trivedi MK, Branton A, Trivedi D, Nayak G, Lee AC, et al. (2016) Impact of biofield energy treated herbomineral formulation (the Trivedi Effect®) on mouse dendritic and splenocyte cells for modulation of pro-inflammatory cytokines. International Journal of Immunology 4(5): 35-45.
  13. Trivedi MK, Mohan TRR (2016) Biofield energy signals energy transmission and neutrinos. American Journal of Modern Physics 5(6): 172-176.
  14. Rubik B (2002) The biofield hypothesis: Its biophysical basis and role in medicine. J Altern Complement Med 8(6): 703-717.
  15. Nemeth L (2008) Energy and biofield therapies in practice. Beginnings 28(3): 4-5.
  16. Rubik B, Muehsam D, Hammerschlag R, Jain S (2015) Biofield science and healing: History, terminology and concepts. Glob Adv Health Med 4: 8-14.
  17. Koithan M (2009) Introducing complementary and alternative therapies. J Nurse Pract 5(1): 18-20.
  18. Barnes PM, Bloom B, Nahin RL (2008) Complementary and alternative medicine use among adults and children: United States. 2007 Natl Health Stat Report 10(12): 1-23.
  19. Trivedi MK, Branton A, Trivedi D, Nayak G, Sethi KK, et al. (2016) Determination of isotopic abundance ratio of biofield energy treated 1,4-dichlorobenzene using gas chromatography-mass spectrometry (GC-MS). Modern Chemistry 4(3): 30-37.
  20. Trivedi MK, Branton A, Trivedi D, Nayak G, Panda P, et al. (2016) Gas chromatography-mass spectrometric analysis of isotopic abundance of 13C, 2H, and 18O in biofield energy treated p-tertiary butylphenol (PTBP). American Journal of Chemical Engineering 4(4): 78-86.
  21. Nayak G, Trivedi MK, Branton A, Trivedi D, Jana S (2018) Evaluation of the effect of consciousness energy healing treatment on the physicochemical and thermal properties of selenium. Journal of New Developments in Chemistry 2(1): 13-23.
  22. Nayak G, Trivedi MK, Branton A, Trivedi D, Jana S (2018) Evaluation of the physicochemical and thermal properties of chromium trioxide (CrO3): Impact of consciousness energy healing treatment. Research & Development in Material Science 8(3): 1-6.
  23. Nayak G, Trivedi MK, Branton A, Trivedi D, Jana S (2018) Evaluation of the physicochemical and thermal properties of consciousness energy healing treated polylactic-co-glycolic acid (PLGA). Journal of Food Science and Technology 5(3): 117-125.
  24. Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M et al. (2015) Evaluation of vegetative growth parameters in biofield treated bottle gourd (Lagenaria siceraria) and okra (Abelmoschus esculentus). International Journal of Nutrition and Food Sciences. 4(6): 688-694.
  25. Nayak G, Trivedi MK, Branton A, Trivedi D, Jana S (2018) Evaluation of the consciousness energy healing treated berberine chloride using PXRD PSA and DSC Analysis. Fsnt 3(6): 000168.
  26. Nayak G, Trivedi MK, Branton A, Trivedi D, Jana S (2018) Impact of Consciousness energy healing treatment on the physicochemical and thermal properties of vitamin D3 (cholecalciferol). Fsnt 3(5): 000162.
  27. Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, et al. (2015) Antimicrobial sensitivity, biochemical characteristics and biotyping of Staphylococcus saprophyticus: An impact of biofield energy treatment. J Womens Health Care 4(6): 271.
  28. Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, Gangwar M, et al. (2015) Antibiogram of multidrug-resistant isolates of Pseudomonas aeruginosa after biofield treatment. J Infect Dis Ther 3(5): 244.
  29. Schellekens RC, Stellaard F, Woerdenbag HJ, Frijlink HW, Kosterink JG (2011) Applications of stable isotopes in clinical pharmacology. Br J Clin Pharmacol 72(6): 879-897.
  30. Weisel CP, Park S, Pyo H, Mohan K, Witz G (2003) Use of stable isotopically labeled benzene to evaluate environmental exposures. J Expo Anal Environ Epidemiol 13(5): 393-402.
  31. Muccio Z, Jackson GP (2009) Isotope ratio mass spectrometry. Analyst 134(2): 213-222.
  32. Rosman KJR, Taylor PDP (1998) Isotopic compositions of the elements 1997 (Technical Report). Pure Appl Chem 70(1): 217-235.
  33. Smith RM (2004) Understanding Mass Spectra: A Basic Approach Second Edition John Wiley & Sons Inc.
  34. Jürgen H (2004) Gross Mass Spectrometry: A Textbook (2nd Edn), Springer: Berlin.
  35. Yamada K, RN El-Shaheny (2015) The influence of pH and temperature on the stability of flutamide. An HPLC investigation and identification of the degradation product by EI+-MS. RSC Adv 5(5): 3206-3214.
Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )